Fertin
Fertin, officially known as Fertin Pharma A/S, is a leading player in the pharmaceutical and healthcare industry, headquartered in Denmark (DK). Founded in 2006, the company has established itself as a pioneer in the development of innovative oral delivery systems, particularly in the field of nicotine replacement therapy and other consumer health products. With a strong presence in Europe and North America, Fertin focuses on creating unique solutions that enhance the efficacy and user experience of medicinal products. Their core offerings include advanced chewing gum and lozenge formulations, which are distinguished by their high bioavailability and consumer-friendly designs. Fertin's commitment to quality and innovation has positioned it as a trusted partner for global brands, earning recognition for its contributions to the industry and its ability to adapt to evolving market demands.
DitchCarbon Score
How does Fertin's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fertin's score of 49 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fertin's reported carbon emissions
In 2023, Fertin Pharma A/S reported total carbon emissions of approximately 6,621,000 kg CO2e, comprising 4,742,000 kg CO2e from Scope 1 and 1,879,000 kg CO2e from Scope 2 emissions. This marks a significant increase from 2022, when the total emissions were about 3,676,000 kg CO2e, and from 2021, which recorded approximately 3,587,000 kg CO2e. The emissions data reflects a corporate family relationship, with figures cascaded from their parent company, Philip Morris International Inc. Fertin has not disclosed any specific reduction targets or initiatives as part of their climate commitments. The absence of Scope 3 emissions data indicates a potential area for future reporting and improvement. The company is currently focusing on its operational emissions, as evidenced by the detailed reporting of Scope 1 and 2 emissions, but lacks comprehensive strategies for upstream and downstream emissions. Overall, while Fertin Pharma A/S has made strides in emissions reporting, the lack of reduction targets and initiatives suggests an opportunity for enhanced climate action and transparency in their sustainability efforts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | - | - | 0,000,000 |
| Scope 2 | - | - | 0,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fertin is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
